BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 24631967)

  • 1. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.
    Do TM; Alata W; Dodacki A; Traversy MT; Chacun H; Pradier L; Scherrmann JM; Farinotti R; Calon F; Bourasset F
    Neuropharmacology; 2014 Jun; 81():311-7. PubMed ID: 24631967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice.
    García-Mesa Y; López-Ramos JC; Giménez-Llort L; Revilla S; Guerra R; Gruart A; Laferla FM; Cristòfol R; Delgado-García JM; Sanfeliu C
    J Alzheimers Dis; 2011; 24(3):421-54. PubMed ID: 21297257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
    Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
    Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
    Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.
    Kelly P; McClean PL; Ackermann M; Konerding MA; Hölscher C; Mitchell CA
    Microcirculation; 2015 Feb; 22(2):133-45. PubMed ID: 25556713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
    Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway.
    Jaffar S; Counts SE; Ma SY; Dadko E; Gordon MN; Morgan D; Mufson EJ
    Exp Neurol; 2001 Aug; 170(2):227-43. PubMed ID: 11476589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice.
    Chen Y; Zhao Y; Dai CL; Liang Z; Run X; Iqbal K; Liu F; Gong CX
    Exp Neurol; 2014 Nov; 261():610-9. PubMed ID: 24918340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microvascular cerebral blood volume changes in aging APP(swe)/PS1(dE9) AD mouse model: a voxel-wise approach.
    Zerbi V; Jansen D; Dederen PJ; Veltien A; Hamans B; Liu Y; Heerschap A; Kiliaan AJ
    Brain Struct Funct; 2013 Sep; 218(5):1085-98. PubMed ID: 22892904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models.
    Nicholson RM; Kusne Y; Nowak LA; LaFerla FM; Reiman EM; Valla J
    Brain Res; 2010 Aug; 1347():179-85. PubMed ID: 20677372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular accumulation of toxic turn amyloid-β is associated with endoplasmic reticulum stress in Alzheimer's disease.
    Soejima N; Ohyagi Y; Nakamura N; Himeno E; Iinuma KM; Sakae N; Yamasaki R; Tabira T; Murakami K; Irie K; Kinoshita N; LaFerla FM; Kiyohara Y; Iwaki T; Kira J
    Curr Alzheimer Res; 2013 Jan; 10(1):11-20. PubMed ID: 22950910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background.
    Lok K; Zhao H; Shen H; Wang Z; Gao X; Zhao W; Yin M
    Neurosci Lett; 2013 Dec; 557 Pt B():84-9. PubMed ID: 24176881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Src signaling and post-synaptic actin polymerization in Alzheimer's disease mice hippocampus--linking NMDA receptors and the reelin pathway.
    Mota SI; Ferreira IL; Valero J; Ferreiro E; Carvalho AL; Oliveira CR; Rego AC
    Exp Neurol; 2014 Nov; 261():698-709. PubMed ID: 25128699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS.
    Woo DC; Lee SH; Lee DW; Kim SY; Kim GY; Rhim HS; Choi CB; Kim HY; Lee CU; Choe BY
    Behav Brain Res; 2010 Jul; 211(1):125-31. PubMed ID: 20307581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REST/NRSF-induced changes of ChAT protein expression in the neocortex and hippocampus of the 3xTg-AD mouse model for Alzheimer's disease.
    Orta-Salazar E; Aguilar-Vázquez A; Martínez-Coria H; Luquín-De Anda S; Rivera-Cervantes M; Beas-Zarate C; Feria-Velasco A; Díaz-Cintra S
    Life Sci; 2014 Oct; 116(2):83-9. PubMed ID: 25261598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Generation of Tau/App/PS1 triple-transgenic mouse model and the study of its biological characteristics].
    Wang LL; Na X; Zhu XN; Chen RZ; Wang H; Wang XL
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2012 Jul; 28(4):294-7. PubMed ID: 23156717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.